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Introduction {#sec005}
============

According to the World Health Organization (WHO) \[[@pone.0233528.ref001]\], chronic infection by hepatitis B virus (HBV) affects 257 million people. It is particularly prevalent in sub-Saharan Africa and in East Asia, affecting 5--10% of all adults, while in North America, less than 1% are infected. The estimated prevalence is less than 5% in eastern Europe, 1.5% in northern Europe, 2% in southern Europe and 1% in western Europe. However, these values are probably underestimates because, among other reasons, the data are obtained from blood donors \[[@pone.0233528.ref002]\]. Moreover, the situation in Europe may be adversely affected by changing patterns of migration \[[@pone.0233528.ref003],[@pone.0233528.ref004]\]. According to a systematic review conducted by the European Centre for Disease Prevention and Control (ECDC) \[[@pone.0233528.ref005]\] based on articles published from 2005 to 2015, the prevalence in Spain was around 0.8% (0.6--1.1) and according to the latest report available \[[@pone.0233528.ref003]\] it was 0.66% (0.34--0.97).

The WHO has reported that 71 million people are infected with hepatitis C virus (HCV) \[[@pone.0233528.ref001]\] and that the most severely affected regions are Europe and the Eastern Mediterranean (2.3%). In Europe, the prevalence of HCV antibodies (anti-HCV) is estimated at 1.1% (95%CI 0.9--1.4) \[[@pone.0233528.ref005]\]. In Spain, the prevalence of antibodies is 1.7% and that of viraemia (HCV RNA positive) is 1.2% \[[@pone.0233528.ref006]\]. In the Ethon Cohort \[[@pone.0233528.ref007]\], the prevalence of anti-HCV positive (anti-HCV+ve) was 1.23% and only 0.32% had viraemia. However, this prevalence might be affected by changes in patterns of migration in Europe, especially in Spain \[[@pone.0233528.ref008]\].

In Spain, the prevalence of HBV infection (surface antigen positive) in pregnant women ranges from 0.1% to 4.4% \[[@pone.0233528.ref005],[@pone.0233528.ref009],[@pone.0233528.ref010]\]. The vertical transmission (VT) of HBV continues to be one of the main routes of infection worldwide \[[@pone.0233528.ref011]\], especially in areas where it is endemic \[[@pone.0233528.ref012]\]. High viral load (VL), which mainly affects HBeAg-positive (HBeAg+ve) women, is the most important risk factor, although women who are HBeAg-negative (HBeAg-ve) and who present high VL are also at risk of transmission \[[@pone.0233528.ref013]\]. In this population, 90% chronicity of infected newborns has been reported \[[@pone.0233528.ref014]\].

The prevalence of anti-HCV in pregnant women in Spain is estimated to be 0.5--1.4% \[[@pone.0233528.ref009],[@pone.0233528.ref015],[@pone.0233528.ref016]\], and the prevalence of viraemia 42--72%. The rate of VT among women with HCV is low, 1--8% in non-coinfected mothers and around 20% in those coinfected with HIV. However, 90% of infected children acquire the virus by VT. The factors related to the VT of HCV are VL and HIV coinfection \[[@pone.0233528.ref017]--[@pone.0233528.ref019]\]. No other factors related to childbirth, epidemiology or breastfeeding have been associated with VT.

Screening for HBV in pregnancy is routinely recommended, as immunoprophylaxis against VT is feasible \[[@pone.0233528.ref012],[@pone.0233528.ref020]\]. According to 2015 data, generalised immunoprophylaxis at birth has reduced the proportion of chronically-infected children aged under five years from 4.7% to 1.3% \[[@pone.0233528.ref001]\]. Nevertheless, up to 10% of newborns whose mothers present high VL become infected \[[@pone.0233528.ref014],[@pone.0233528.ref021]\]. Accordingly, it is recommended that in HBV+ve women, VL should be assessed at 24 weeks of pregnancy and antiviral treatment administered if the VL is high. On the other hand, the determination of HCV in pregnancy is only recommended for at-risk populations such as intravenous drug users, women with high-risk sexual practices, women with HIV coinfection and women born in countries with high endemicity for HCV. In consequence, the prevalence reported in the literature may not correspond to reality. Prophylactic and therapeutic measures to eradicate HBV and HCV are currently being implemented. Children infected by VT should be included in this programme, but screening during pregnancy for HCV is not yet universal, and therefore some children who acquire the virus through VT will remain undiagnosed.

In view of these considerations, the main aim of this study is to determine the prevalence of HBV and HCV in pregnant women in Spain, taking into account their country of origin, epidemiological factors and the risk of VT.

Material and method {#sec006}
===================

Patients {#sec007}
--------

To determine the prevalence of HBV and HCV among a population of pregnant women, a multicentre prospective open-label cohort study was carried out from January to December 2015. The following hospitals took part: Hospital Universitario 12 de Octubre Madrid (HU12O), Hospital Universitario La Paz Madrid (HULP), Hospital Universitario San Cecilio Granada (HUSC), Hospital Universitario Virgen de las Nieves Granada (HUVN), Hospital Universitario Central de Asturias Oviedo (HUCA), Hospital Universitario Torrecárdenas Almería (HUT), Hospital Universitario Virgen del Rocío Sevilla (HUVR) and Hospital Universitario Virgen de la Victoria Málaga (HUVV).

The population analysed in the HBV prevalence study consisted of 21870 pregnant women, whose data were provided by the researchers at each hospital, from an anonymised database managed by its Microbiology Service, which compiles and manages these data as usual clinical practice in pregnancy. After the delivery, the mothers found to be HBV-positive (HBV+ve) were invited to participate in the study, by completing the epidemiological survey, stating their country of origin and providing details of the delivery. In every case, the mother's informed consent was obtained. In addition, the donation of blood samples from each mother and child was requested, together with consent for medical follow-up of the neonate for 18 months. [Fig 1](#pone.0233528.g001){ref-type="fig"} shows the flow chart for the recruitment of these participants.

![Flow chart for selection of participants.\
This figure shows the flow chart of pregnant women recruitment for prevalence, epidemiological and risk factors for vertical transmission studies.](pone.0233528.g001){#pone.0233528.g001}

In Spain, the determination of HCV does not form part of usual clinical practice, and so informed consent in this respect was requested and obtained in every case included in this study. Accordingly, tests for HCV were performed on 7659 women in week 12 of pregnancy, during the scheduled hospital visit for the detection of chromosomopathies. After the delivery, the mothers found to be HCV positive (HCV+ve) were invited to participate in the study, by completing the epidemiological survey, stating their country of origin and providing details of the delivery. In every case, informed consent in this respect was obtained. In addition, the donation of blood samples from the mother and child was requested, together with consent for medical follow-up of the neonate for 18 months. [Fig 1](#pone.0233528.g001){ref-type="fig"} shows the flow chart for the recruitment of these participants.

The inclusion criteria were HBV surface antigen positive (HBsAg+ve) or anti-HCV+ve status confirmed by enzyme-linked immunosorbent assay (ELISA) and the provision of informed consent.

Epidemiological study {#sec008}
---------------------

The study variables were participant's age, country of origin and risk factors for infection. The risk factors considered were transfusion, intravenous drug abuse (IVDA), tattoos, piercing, surgery, dental treatment, infected partner, high-risk sexual practices, history of infection in the participant's mother or siblings and HIV coinfection, categorised as yes, no or unknown. The survey also asked whether the woman knew about the infection prior to her pregnancy. The route of transmission of infection was categorised as vertical, parenteral, sexual or unknown.

Risk factors for vertical transmission {#sec009}
--------------------------------------

Antigen E (HBeAg) and antibody E (anti-HBe) were analysed for HBV, and VL was analysed for HBV and/or HCV.

The HBV+ve women were classified according to the EASL Clinical Practice Guidelines \[[@pone.0233528.ref022]\] as HBeAg-positive chronic infection (HBeAg+ve and DNA \>10^7^ IU/mL), HBeAg-positive chronic hepatitis (HBeAg+ve and DNA 10^4^−10^7^ IU/mL), HBeAg-negative chronic infection (HBeAg-ve and DNA \<2000 IU/mL) and HBeAg-negative chronic hepatitis (HBeAg-ve and DNA \>2000 IU/mL).

Other information compiled for the study included data on the pregnancy and delivery, including in vitro fertilisation, antiviral treatment for HBV during pregnancy, type of delivery, gestational age, time elapsed since the breaking of the waters, weight, Apgar score of the neonate at birth and the type of lactation.

The study protocol is the same as has been described in previous studies by this research group (17--19).

Analysis of the differences between HBV and HCV {#sec010}
-----------------------------------------------

The dependent variable was HBV+ve versus HCV+ve. The remaining variables were assumed to be independent.

Virologic assays {#sec011}
----------------

The serological determination of HBsAg, anti-HCV and anti-HIV was carried out by commercial ELISA, which is routinely used in the laboratories of each of the participating hospitals.

The VL of HBV and/or HCV was determined by COBAS TaqMan (cut-off \<12 IU/mL, \<15 IU/mL. Roche Diagnostics, respectively), distinguishing between not detected, below cut-off but not quantifiable and greater than cut-off and quantifiable. In the HBV+ve women, HBeAg and anti-HBe were also determined.

Statistical analysis {#sec012}
--------------------

In our statistical analysis, the quantitative variables are described by the mean and the standard deviation, or in cases of non-normal distribution, by the median and the interquartile range. The qualitative variables are presented as absolute and relative frequencies. The corresponding prevalences and 95% confidence intervals were also calculated. The inter-group differences were determined by bivariate analysis, using Pearson's chi-square test or Fisher's exact test for the qualitative variables and Student's t test or the Mann-Whitney U test for the continuous ones. The normality of the data distribution was examined by the Kolmogorov-Smirnov test. A p-value \<0.05 was considered significant. All data analyses were performed using IBM SPSS 19 statistical software.

Ethical considerations {#sec013}
----------------------

This study was carried out in accordance with the ethical guidelines of the Declaration of Helsinki of 1975, revised in 2013. All participants gave written and verbal informed consent. The study protocol was firstly approved by Comité Ético de Investigación Provincial de Granada (Ethics Committee of the Principal Investigator's hospital) and later by the Ethics Committee at each participating hospital. The relevant provisions of Spanish data protection legislation were respected in all phases of the study.

Results {#sec014}
=======

Prevalence of HBV and HCV in pregnancy {#sec015}
--------------------------------------

The prospective cohort for the HBV study consisted of 21870 pregnant women, of whom 91 were HBsAg+ve, with a prevalence of 0.42% (95% CI 0.33--0.50). [Table 1](#pone.0233528.t001){ref-type="table"} shows the distribution among the participating hospitals. The cohort for the HCV study contained 7659 women, of whom 20 were anti-HCV+ve, with a prevalence of 0.26% (95% CI 0.15--0.38). The prevalence of HBV differed significantly among the hospitals (p = 0.013), lowest at HUCA and highest at HULP, HUT and HUVR. On the other hand, the inter-hospital differences for anti-HCV prevalence were not significant (p = 0.52).

10.1371/journal.pone.0233528.t001

###### Seroprevalence of HBV and HCV among pregnant women at each hospital.

![](pone.0233528.t001){#pone.0233528.t001g}

  ----------------------------------------------------------------------------------------- ---------------- ----------- ---------------- ----------------
  **HBV**                                                                                   Positive cases   Women (n)   Prevalence (%)   95%CI
  HU12O[^a^](#t001fn001){ref-type="table-fn"}                                               18               4224        0.42             0.22--0.62
  HULP[^b^](#t001fn002){ref-type="table-fn"}                                                17               2901        0.59             0.31--0.86
  HUSC[^c^](#t001fn003){ref-type="table-fn"} --HUVN[^d^](#t001fn004){ref-type="table-fn"}   9                2262        0.39             0.14--0.66
  HUCA[^e^](#t001fn005){ref-type="table-fn"}                                                1                2362        0.04             0.01--0.12
  HUT[^f^](#t001fn006){ref-type="table-fn"}                                                 13               2037        0.64             0.29--0.98
  HUVR[^g^](#t001fn007){ref-type="table-fn"}                                                29               5903        0.49             0.32--0.67
  HUVV[^h^](#t001fn008){ref-type="table-fn"}                                                4                2181        0.18             0.004--0.362
  **Total**                                                                                 **91**           **21870**   **0.42**         **0.33--0.50**
  **HCV**                                                                                   Positive cases   Women (n)   Prevalence (%)   95%CI
  HULP[^b^](#t001fn002){ref-type="table-fn"}                                                7                2901        0.24             0.06--0.42
  HUSC[^c^](#t001fn003){ref-type="table-fn"} --HUVN[^d^](#t001fn004){ref-type="table-fn"}   2                903         0.22             0.01--0.53
  HUCA[^e^](#t001fn005){ref-type="table-fn"}                                                5                1713        0.29             0.04--0.55
  HUT[^f^](#t001fn006){ref-type="table-fn"}                                                 3                1671        0.18             0.01--0.38
  HUVV[^h^](#t001fn008){ref-type="table-fn"}                                                3                471         0.64             0.01--1.34
  **Total**                                                                                 **20**           **7659**    **0.26**         **0.15--0.38**
  ----------------------------------------------------------------------------------------- ---------------- ----------- ---------------- ----------------

^a^HU12O: Hospital Universitario 12 de Octubre, Madrid.

^b^HULP: Hospital Universitario La Paz, Madrid.

^c^HUSC: Hospital Universitario San Cecilio, Granada.

^d^HUVN: Hospital Universitario Virgen de las Nieves, Granada.

^e^HUCA: Hospital Universitario Central de Asturias, Oviedo.

^f^HUT: Hospital Universitario Torrecárdenas, Almería.

^g^HUVR: Hospital Universitario Virgen del Rocío, Sevilla.

^h^HUVV: Hospital Universitario Virgen de la Victoria, Málaga.

Epidemiology and risk factors for vertical transmission in HBV-positive women {#sec016}
-----------------------------------------------------------------------------

Of the 67 women included in the study, 31 (46.3%) were aware of the infection prior to pregnancy. None were coinfected with HCV, and there was one case (1.5%) of coinfection with HIV. By country of birth, 22 (32.8%) were Spanish, followed in frequency by those from China and Eastern Europe ([Fig 2](#pone.0233528.g002){ref-type="fig"}). The risk factors for infection in these pregnant women are shown in [Table 2](#pone.0233528.t002){ref-type="table"}. The route of transmission was parenteral in 14 cases (20.9%), vertical in 21 (31.3%), sexual in 3 (4.5%) and unknown in 27 (40.3%). Of the women presenting VT, 13 (61.9%) were of foreign origin.

![Geographic origin of pregnant women with HBV or HCV infection.\
This figure shows the geographic origin of the pregnant women with HBV or HCV infection who participated in the epidemiological study, expressed in relative frequency.](pone.0233528.g002){#pone.0233528.g002}

10.1371/journal.pone.0233528.t002

###### Epidemiology of pregnant women infected with HBV or HCV.

![](pone.0233528.t002){#pone.0233528.t002g}

                                                             HBV n = 67      HCV n = 20          P
  ---------------------------------------------------------- --------------- ------------------- ---------
  **Median age of the mother** \[P25-P75\]                   33 \[28--37\]   34 \[32.2--35.7\]   0.106
  **Aware of infection**                                     31 (46.3%)      13 (65%)            0.128
  **Co-infection with HIV**                                  1 (1.5%)        2 (10%)             0.125
  **Country of origin**                                                                          
  Spain                                                      22 (32.8%)      11 (55%)            0.070
  Other                                                      44 (65.7%)      9 (45%)             
  **Transfusion**                                            1 (1.5%)        3 (15%)             0.043
  **IVDA**[^a^](#t002fn001){ref-type="table-fn"}             0 (0%)          9 (45%)             \<0.001
  **Tattoo**                                                 6 (9%)          2 (10%)             1
  **Piercing**                                               3 (4.5%)        1 (5%)              1
  **Surgery**                                                13 (19.4%)      6 (30%)             0.383
  **Dental treatment**                                       4 (6%)          1 (5%)              1
  **Infected partner**                                       3 (4.5%)        3 (15%)             0.143
  **High-risk sexual practices**                             3 (4.5%)        3 (15%)             0.148
  **Family history**[^b^](#t002fn002){ref-type="table-fn"}   21 (31.3%)      0 (0%)              0.001
  **Unknown route of infection**                             27 (40.3%)      4 (20%)             0.066

^a^IVDA: Intravenous drug abuse.

^b^Family history: previous infection in the mother or siblings.

Of the 62 HBsAg+ve women who provided samples, 42 (67.7%) had viraemia. Nine (14.5%) were HBeAg+ve and one (with a twin pregnancy) had chronic infection with a VL of 2070 IU/mL at the moment of delivery. Of the eight women who had HBeAg+ve chronic infection, six were treated during pregnancy: three achieved undetectable VL before delivery and in the other three the maximum VL was 1448 IU/mL. The two HBeAg+ve women who were not treated had a VL \>10^8^ IU/mL. Two of the HBeAg+ve women were Spanish, five were Chinese, one was from Central America and one was from sub-Saharan Africa. The ten neonates were monitored after birth, and none became infected. Of the 53 (85.5%) women who were HBeAg-ve, 40 had chronic infection and 13 had chronic hepatitis.

None of the pregnancies was achieved by in vitro fertilisation. The birth was spontaneous in 47 (72.3%) cases, by caesarean section in 13 (20%) (two of which were scheduled) and by instrumental delivery in five (7.7%). The data for the 69 neonates are summarised in [Table 3](#pone.0233528.t003){ref-type="table"}. Only one of the low-weight children had a maternal history of antiviral treatment. Of the 30 neonates in whom the VL was analysed at birth, two were HBV+ve, although later tests were negative. All of the neonates born to HBsAg+ve women received immunoprophylaxis during the first twelve hours of life, for an average of 3.4 ± 3 hours. The ten children born to HBeAg+ve women received immunoprophylaxis in the first three hours of life. None of the 54 children who completed the follow-up became infected.

10.1371/journal.pone.0233528.t003

###### Characteristics of the neonates born to HBV or HCV-positive mothers.

![](pone.0233528.t003){#pone.0233528.t003g}

                                                                                HBV n = 69     HCV n = 20     P
  ----------------------------------------------------------------------------- -------------- -------------- -------
  **Premature**[^a^](#t003fn001){ref-type="table-fn"}                           8 (11.6%)      4 (20%)        0.265
  **Weight** (g) Mean ± standard deviation                                      3194.7 ± 681   2998.8 ± 582   0.248
  **Time elapsed since breaking of the waters (h)** Mean ± standard deviation   7 ± 8          12 ± 17        0.212
  **Apgar score** Median \[P25-P75\]                                            9 \[5--10\]    9 \[6--10\]    0.834
  **Breastfeeding**                                                             55 (86%)       13 (65%)       0.044

^a^Premature: gestational age \<37 weeks.

Epidemiology and risk factors for vertical transmission in HCV-positive women {#sec017}
-----------------------------------------------------------------------------

Thirteen women (65%) were previously aware of their HCV infection. None were coinfected with HBV and there were two cases (10%) of coinfection with HIV. By country of origin, the majority of women were from Spain (11 cases, 55%) and Eastern Europe (four cases, 20%) ([Fig 2](#pone.0233528.g002){ref-type="fig"}). The risk factors for infection are detailed in [Table 2](#pone.0233528.t002){ref-type="table"}. The route of transmission was parenteral in 16 women (80%), of whom nine had a history of IVDA. The route of transmission was unknown in four cases (20%).

HCV RNA was positive (HCV-RNA+ve) in eight (40%) of the 20 women, with an average VL of 1.9x10^5^ IU/mL (4.4x10^5^--3.5x10^6^ IU/mL). The distribution of genotypes was 1b (25%), 3 (25%), 4c (12.5%) and unknown (37.5%).

None of the pregnancies was achieved by in vitro fertilisation. Delivery was spontaneous in 12 cases (60%), by caesarean section in four (20%) and by instrumental delivery in four (20%). The data for the 20 neonates are summarised in [Table 3](#pone.0233528.t003){ref-type="table"}. Five children of the eight women with viraemia completed the follow up and none became infected.

Analysis of the differences between HBV and HCV-positive pregnant women {#sec018}
-----------------------------------------------------------------------

As can be seen in [Table 2](#pone.0233528.t002){ref-type="table"}, 65.7% (44/67) of the women with HBV were foreign born, versus only 45% (9/20) of the women with HCV. Nevertheless, the difference was not statistically significant (p = 0.07). A similar pattern was observed for the unknown route of maternal infection, which was more frequent among the women with HBV than those with HCV (40.3% vs. 20%; p = 0.066). VT as the mechanism of infection was more frequent for the HBV+ve women (31.3% vs. 0%; p = 0.001), while IVDA was more frequent in the HCV group (45% vs. 0%; p\<0.001). Previous blood transfusion was also significantly higher in the HCV group (15% vs. 1.5%; p = 0.043).

There were no statistically significant differences among the neonates for any of the variables analysed, except that a significantly lower proportion of the women with HCV breastfed their children (65% vs. 86%; p = 0.044) ([Table 3](#pone.0233528.t003){ref-type="table"}).

Discussion {#sec019}
==========

In our study population, the prevalence of HBV was 0.42% (91/21870) and that of HCV was 0.26% (20/7659). The HBV+ve women were more likely to be foreign born than those with HCV. The most frequent route of transmission of HBV was of unknown origin, while among those of known origin, VT was most commonly observed. Regarding the risk factors for VT, 67.7% of the women presenting HBV had viraemia and 14.5% were HBeAg+ve. Immunoprophylaxis was administered correctly to all the neonates born to HBV+ve mothers. Among the HCV+ve mothers, the parenteral route of transmission was most common, mainly due to IVDA. In the HCV group, 40% had viraemia and 10% were co-infected with HIV. The HCV+ve women were less likely than HBV+ve to breastfeed their children.

In this study, the observed prevalence of HBsAg+ve was significantly different among the participant hospitals. The highest level was obtained for the HUT in Almeria (0.64%), a hospital that serves a large migrant population from North and sub-Saharan Africa. In contrast, the data for anti-HCV prevalence were fairly consistent among the participant hospitals, with the sole exception of the HUVV in Malaga, where the prevalence was higher, although in this case the sample size was very small.

In the general population in Spain, the prevalence of HBV is 0.66% (0.34--0.97) \[[@pone.0233528.ref003]\], which is higher than the prevalence we found in pregnant women. In a previous study conducted in 1986--89 \[[@pone.0233528.ref023]\] at the HUSC in Granada, based on a population of 4450 pregnant women, the prevalence of HBV was 1.53% (95% CI 1.14--1.92). Thirty years later, according to our findings, the prevalence in this city has fallen to 0.39%. For comparison, a 2009 study by Salleras *et al*. \[[@pone.0233528.ref024]\], with a population of pregnant women in Catalonia, and which has been taken as a benchmark for Spain by the ECDC \[[@pone.0233528.ref005]\], recorded a very low prevalence, of 0.1%.

Our findings show that 65.7% of the participants who were HBV+ve were foreign born, with a particularly strong presence of women from China and eastern Europe, which corroborates the pattern reported previously \[[@pone.0233528.ref025],[@pone.0233528.ref026]\]. In a study conducted in Madrid \[[@pone.0233528.ref026]\], the highest rate of seropositivity was found among women from Romania and other Eastern European countries (23.7%), followed by those from China (20.3%) and sub-Saharan Africa (18.6%). In recent years, the prevalence of HBV in Spain has tended to decrease, and if the population considered excluded those of foreign origin, the prevalence would probably be even lower.

In most of the cases analysed in our study, the route of transmission of HBV infection was unknown, while the most common of the known routes was maternal family history of HBV infection (31.3%), although some women presented several risk factors for infection. A large majority of the women (67.7%) had viraemia and therefore were potential transmitters of infection. 14.5% were HBeAg+ve, which increased the risk of transmission still further. However, only six of these women received antiviral treatment during their pregnancy, which shows that not all hospitals follow clinical practice guidelines in this respect \[[@pone.0233528.ref022]\]. A previous study carried out in Granada with 4169 pregnant women \[[@pone.0233528.ref025]\] reported that HBV was present in 27, of whom only one (a woman of Asian origin) was HBeAg+ve.

All of the 69 neonates born to HBV+ve mothers received immunoprophylaxis during the first twelve hours of life, and the ten children born to HBeAg+ve women received immunoprophylaxis in the first three hours of life. None of the 54 neonates who completed the follow up became infected. This includes the two children of HBeAg+ve women with high VL who were untreated, which highlights the importance of correctly administering immunoprophylaxis to neonates at an early stage of life.

In our study, the prevalence of HCV was 0.26%, and only 40% of these cases were HCV-RNA+ve. On the other hand, previous studies in the general population have found a higher prevalence, of 1.7% (0.4--2.6), with HCV-RNA+ve in 68.6% of these cases \[[@pone.0233528.ref027]\]. Nevertheless, research has shown that the prevalence of HCV is lower among women than in the general population. In a study conducted in the United States \[[@pone.0233528.ref028]\], the prevalence in men was 1.56% versus 0.75% in women. In another study, also conducted in the USA \[[@pone.0233528.ref029]\], with 87924 pregnant women, the prevalence of HCV was 1.2%. In Navarre (Spain), a study of 7314 pre-surgical patients \[[@pone.0233528.ref030]\] revealed a prevalence of 0.94%, with higher values for men than for women (1.25% vs. 0.62%, p = 0.0049). Finally, a study carried out in 1993--95 with 3003 pregnant women at the HUSC in Granada \[[@pone.0233528.ref019]\] reported that only 19 were HCV+ve (0.63%) while 14 (74%) presented viraemia. Thus, the value of 0.26% obtained in the present study is much lower than these previous findings.

Among our study population, 55% of the women with HCV were Spanish, followed in frequency by those from Eastern Europe (20%), which is in line with previous findings \[[@pone.0233528.ref031]\]. According to earlier research \[[@pone.0233528.ref027]\], 80% of the cases recorded worldwide with positive viraemia are located in 31 countries, one of which is Spain, but over half of the infections correspond to just six countries: China, Pakistan, Nigeria, Egypt, India and Russia. Parenteral transmission is the most common route of infection, and most cases involve a history of IVDA, although in 20% of cases the origin of the infection is not known. This knowledge gap could justify the introduction of HCV screening in pregnancy. Similar findings have been reported in other studies \[[@pone.0233528.ref029],[@pone.0233528.ref032],[@pone.0233528.ref033]\]. Infection is significantly more frequent in people aged under 30 years, those who are of European descent, especially those from Eastern Europe, and those with a history of IVDA. The most frequent genotypes recorded in our study were 1b and 3, followed by 4, which is consistent with previous research findings \[[@pone.0233528.ref033]\]. Two women (10%) had co-infection by HIV, which increases the probability of HCV being transmitted to the child \[[@pone.0233528.ref017]\].

Among the children of women with HCV infection, 20% were premature, a value that is higher than in the general population. Moreover, only 65% initiated breastfeeding, which is well below the figure for children of HBV+ve mothers (86%) and the general population. These findings may be more influenced by the history of IVDA than by the HCV *per se* \[[@pone.0233528.ref034]\]. This may also be the reason why not all the children of mothers with viraemia completed the follow up.

Among the specific characteristics differentiating the HBV+ve women were the predominance of infection by VT and the larger proportion who breastfed their children. In addition, more were foreign born, compared to the women with HCV. In the HCV group, the main distinguishing features observed were blood transfusion and a history of IVDA.

The main limitation of this study concerned the determination of HCV in the pregnant women, since screening for this condition is not universal in Spain during pregnancy, and therefore signed informed consent was required. For this reason, the sample size for our analysis of HCV prevalence was lower than that for HBV. Furthermore, some of the Spanish hospitals that were invited declined to participate. Another limitation concerned the follow-up of the children of seropositive mothers; many of these children were adopted after birth and so their place of residence changed.

In summary, the prevalences of HBV and HCV that we report are lower than those documented previously. A significant number of the women with HBV were foreign born and/or had a maternal family history of infection. Among those with HCV, many had a history of IVDA, which probably influenced the fact that these women were less likely to complete follow up and less likely to breastfeed their children. Over half of the women with HBV had viraemia, and therefore were potential transmitters of the infection to the neonate. Therefore, the provision of appropriate immunoprophylaxis (including immunoglobulin therapy and vaccination) is important in neonates born to HBV+ve mothers. However, among the women with HCV, despite the presence of viraemia and coinfection with HIV, there was no transmission to the children.

We thank Pedro Lucas at FIBAO (Public Foundation for Biomedical Research in Eastern Andalusia) for designing the database used in this study.

This paper will be presented by Maria del Mar Diaz-Alcazar to obtain her Ph.D. within the doctoral programme 'Clinical Medicine and Public Health' at the University of Granada (Spain).
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We would appreciate receiving your revised manuscript by May 22 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Anna Kramvis

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. Please note that according to our submission guidelines (<http://journals.plos.org/plosone/s/submission-guidelines>), outmoded terms and potentially stigmatizing labels should be changed to more current, acceptable terminology. For example: "Caucasian" should be changed to "white" or "of \[Western\] European descent" (as appropriate).

3\. Please include additional information regarding the survey or questionnaire used in the study and ensure that you have provided sufficient details that others could replicate the analyses. For instance, if you developed a questionnaire as part of this study and it is not under a copyright more restrictive than CC-BY, please include a copy, in both the original language and English, as Supporting Information. Moreover, please include more details on how the questionnaire was pre-tested, and whether it was validated.

Additional Editor Comments (if provided):

Please pay special attention to all the reviewers\' comments and suggestions in particular paying special attention in improving the English language and grammar.

There are a number of errors even in the abstract: correct terminology for \"E antigen\" is HBeAg - please correct here and in the rest of the manuscript where it is referred to as \"AgHBe\". \"VHB\" should be HBV is assume, correct in the abstract and in all other sections of the manuscript. The comment of the prevalence being different to previous studies is not correct considering that here you only looked at prevalence in females. Please consider correcting this. The statement in the abstract \"all neonates received immunoprophylaxis\" I assume this is all neonates born to HBV+ve mothers! Thus please correct here and in the rest of the manuscript.

What is not clear is whether there is an overlap between the pregnant women tested for HBV and those for HCV. Please clarify!!

Where the ethical considerations the same for both HBV and HCV studies? Were separate protocols submitted to the institutional review boards?

Was the prevalence between the different hospitals significantly different? Could you explain why for example HUCA had 0.04% whereas HUT had 0.64% HBV prevalence? Were the population groups serviced different between the two hospitals? You do mention in your discussion that HUT had more pregnant women of foreign origin. Were they mainly from eastern Europe, China or sub-Saharan Africa? Another important analysis that would add value to your study, would be to compare the number of HBeAg-positivity between Spanish women, and the various immigrant populations, i.e. Chinese compared to European and African. It has important implications regarding the management of HBV infection. For example mother to child transmission is more frequent in Asian populations compared to Africans because of differences in the frequency of HBeAg-positivity in the two groups.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The study by Ruiz-Extremera et al., entitled "Seroprevalence, epidemiology and clinical characteristics of hepatitis B and C viruses in pregnant women in Spain" aimed to study the prevalence of HBV/HCV in pregnant women, subsequent vertical transmission, and newborn immune prophylaxis etc. Additionally, the data was analyzed in view of human migration to identify other possible/associated risk factors.

The study is concise, addressing certain important issues like, the need for proper immune prophylaxis, probable nation wide vaccination program etc. Still further modifications are needed before deemed fit for acceptance. Some concerns that need to be addressed are as follows:

Some major points are:

1\. The whole MS needs linguistic correction. For eg. In the abstract section: vide line no. 38-39 "HBV prevalence was analyzed in a population of 21,870 women and that of HCV, in one of 7,659 ". In the line "that of HCV, in one of 7,659" does mean only one subject was positive out of 7659 subjects".

I think a better way of representation is "HBV prevalence was analyzed in a population size of 21,870 women and for HCV, the study population size was 7,659 women".

Another eg. Line no 83 , "chronification" should be "chronicity".

2\. For any data represented with percentages should accompany the numerical ration to ease things for understanding and more meaningful. Viz. line no. 43 "HBV prevalence was 0.42% and that of HCV, 0.26%" should be "HBV prevalence was 0.42% (91/21870) and that of HCV, 0.26% (20/7659)". Also, it is better to mention the table number.

3\. In the discussion section, vide line no. 298-299 "In the general population in Spain, the prevalence of HBV is 0.66% (0.34-0.97) (3), which is higher than was recorded in the present research". As HBV chronicity display gander disparity, thus probably, this difference is expected. It will be better to comment on that.

4\. This reviewer suggests including and discussing the importance of HBV vaccination in the conclusion section.

Reviewer \#2: Line 38 Methodology. Multicentre open-cohort study performed during 2015. Which period of 2015?

The papers\' english needs thorough grammar revision.

Examples ( Line 49. Viraemia was present in 40% and 10% were co-infected with HIV .

Line 75. only 0.32%. This prevalence could be modified by changes in patterns of migration

Line 76. towards the European Union in general and Spain, in particular (8).

Line 100. HIV coinfection or pregnant women from countries where HCV is endemic )

Figure 1 Diagram labelling is not very clear.

Figure 2 needs labelling

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0233528.r003

Author response to Decision Letter 0

3 May 2020

We would like to thank you for the suggestions provided regarding the article entitled "Seroprevalence and epidemiology of hepatitis B and C viruses in pregnant women in Spain. Risk factors for vertical transmission" by the authors Ángeles Ruiz-Extremera, María del Mar Díaz-Alcázar, José Antonio Muñoz-Gámez, et al. As requested, we provide more information in the rebuttal letter about the changes made to the manustript.

We very much appreciate the comments and suggestions made, which have been very helpful in improving the manuscript. We hope these changes are considered appropriate and that the manuscript is now suitable for publication. In any case, we will gladly consider any further comments you may have.

###### 

Submitted filename: Response to Reviewers.doc

###### 

Click here for additional data file.
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Academic Editor

© 2020 Anna Kramvis
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This is an open access article distributed under the terms of the
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, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
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Dear Dr. Díaz Alcázar,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Anna Kramvis

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

10.1371/journal.pone.0233528.r005
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Academic Editor

© 2020 Anna Kramvis

2020

Anna Kramvis

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
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Seroprevalence and epidemiology of hepatitis B and C viruses in pregnant women in Spain. Risk factors for vertical transmission.

Dear Dr. Díaz-Alcázar:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof. Anna Kramvis

Academic Editor

PLOS ONE
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